2018 | AbbVie (a Division of Abbott Laboratories, Limited) | Orilissa - 150 mg/tablet | elagolix (elagolix sodium) | 02481332 | moderate to severe pain associated with endometriosis | 30 Oct 2018 | Within Guidelines |
2018 | Aerie Pharmaceuticals, Inc. | Rhopressa - 0.2 mg/mL | netarsudil | | reduction of elevated intraocular pressure (IOP) | 06 Nov 2018 | Within Guidelines |
2018 | Alexion Pharmaceuticals Inc. | KANUMA - 2 mg/mL | sebelipase alfa | 2469596 | Lysosomal acid lipase deficiency | 10 Apr 2018 | Within Guidelines |
2018 | Alexion Pharmaceuticals Inc. | STRENSIQ - 40 mg/mL | asfotase alfa | 2444631 | Paediatric-onset Hypophosphatasia | 23 Jan 2018 | Does Not Trigger Investigation |
2018 | Allergan Inc. | Restasis Multidose - 0.5 mg/mL | cyclosporine | 02476835 | moderate to moderately severe aqueous deficient dry eye disease | 09 Jul 2018 | Within Guidelines |
2018 | Allergan Inc. | CONSTELLA - 72 mcg/capsule | linaclotide | 2469510 | Irritable bowel syndrome | 30 Mar 2018 | Within Guidelines |
2018 | Amicus Therapeutics UK Ltd. | Galafold - 123 mg/capsule | migalastat hydrochloride | 2468042 | Fabry disease | 14 Jan 2018 | Subject to Investigation |
2018 | AstraZeneca Canada Inc. | Imfinzi - 50 mg/mL | durvalumab | 2468816 | Cancer | 20 Nov 2017 (Patented 27 Feb 2018) | Within Guidelines |
2018 | AstraZeneca Canada Inc. | LYNPARZA - 100 mg/tablet | olaparib | 2475200 | Cancer | 23 May 2018 | VCU |
2018 | AstraZeneca Canada Inc. | LYNPARZA - 150 mg/tablet | olaparib | 2475219 | Cancer | 23 May 2018 | VCU |
2018 | AstraZeneca Canada Inc. | FASENRA - 30 mg/dose | benralizumab | 2473232 | Eosinophilic asthma | 28 Mar 2018 | Within Guidelines |
2018 | Avir Pharma Inc. | ZEVTERA - 500 mg/vial | ceftobiprole medocaril | 2446685 | Pneumonia | 21 Mar 2018 | Within Guidelines |
2018 | Avir Pharma Inc. | Cresemba - 200 mg/vial | isavuconazole (isavuconazonium sulfate) | 02483998 | antifungal | 19 Oct 2018 | Within Guidelines |
2018 | Bausch Health, Canada Inc. | Siliq - 210 mg/syringe | brodalumab | 02473623 | moderate to severe plaque psoriasis | 05 Jul 2018 | Within Guidelines |
2018 | Baxalta Canada Corporation | Rixubis - 3000 unit/vial | nonacog gamma | 2431963 | Hemophilia B | 5 Dec 2017 | Subject to Investigation |
2018 | Bayer Inc. | Xarelto - 2.5 mg/tablet | rivaroxaban | 02480808 | prevention of venous thromboembolic events | 28 Sep 2018 | Within Guidelines |
2018 | Bristol-Myers Squibb Canada Co. | Opdivo - 100 mg/vial | nivolumab | 02446634 | unresectable or metastatic BRAF V600 wild-type melanoma | 26 Oct 2015 | Within Guidelines |
2018 | Bristol-Myers Squibb Canada Co. | Opdivo - 40 mg/vial | nivolumab | 02446626 | unresectable or metastatic BRAF V600 wild-type melanoma | 26 Oct 2015 | Within Guidelines |
2018 | Cipher Pharmaceuticals Inc. | BRINAVESS - 20 mg/mL | vernakalant hydrochloride | 2462400 | Atrial fibrillation | 23 Jan 2018 | Within Guidelines |
2018 | Cipher Pharmaceuticals Inc. | Ozanex - 10 mg/gram | ozenoxacin | 2463504 | Impetigo | 4 Jan 2018 | Within Guidelines |
2018 | Eisai Limited | Lenvima - 8 mg/day | lenvatinib mesylate | 2468220 | Cancer | 7 May 2018 | Within Guidelines |
2018 | Eisai Limited | Lenvima - 18 mg/day | lenvatinib mesylate | 2468239 | Cancer | 7 May 2018 | Within Guidelines |
2018 | Eli Lilly Canada Inc. | LARTRUVO - 500 mg/vial | olaratumab | 2469227 | Cancer | 22 Dec 2017 | Subject to Investigation |
2018 | Eli Lilly Canada Inc. | Olumiant - 2 mg/tablet | baricitinib | 02480018 | moderate to severe rheumatoid arthritis | 27 Sep 2018 | Within Guidelines |
2018 | EMD Serono Canada Inc. | BAVENCIO - 20 mg/mL | avelumab | 2469723 | Cancer | 19 Dec 2017 | Within Guidelines |
2018 | Gilead Sciences, Inc. | Biktarvy 25/50/200 - 275 mg/tablet | bictegravir (bictegravir sodium)/emtricitabine/tenofovir alafenamide (tenofovir alafenamide hemifumarate) | 02478579 | human immunodeficiency virus-1 | 08 Aug 2018 | Within Guidelines |
2018 | GlaxoSmithKline Inc. | BENLYSTA - 200 mg/mL | belimumab | 2470489 | Lupus | 14 May 2018 | Subject to Investigation |
2018 | GlaxoSmithKline Inc. | Shingrix - 50 mcg/dose | herpes zoster vaccine (non-live recombinant, AS01B adjuvanted) | 2468425 | Shingles | 2 Jan 2018 | Subject to Investigation |
2018 | GlaxoSmithKline Inc. | TRELEGY ELLIPTA 100/62.5/25 - 187.5 mcg/dose | fluticasone furoate/umeclidinium/vilanterol | 2474522 | Chronic obstructive pulmonary disease | 30 May 2018 | Within Guidelines |
2018 | Hoffmann-La Roche Limited | Rituxan SC - 120 mg/mL | rituximab | 2473976 | Cancer | 24 Apr 2018 | Within Guidelines |
2018 | Hoffmann-La Roche Limited | Alecensaro - 150 mg/capsule | alectinib | 2458136 | Cancer | 14 Oct 2016 (Patented 2 Jan 2018) | Within Guidelines |
2018 | Hoffmann-La Roche Limited, Canada | Kadcyla - 160 mg/vial | trastuzumab emtansine | 02473224 | HER2-positive, metastatic breast cancer | 24 Oct 2018 | Does Not Trigger Investigation |
2018 | Hoffmann-La Roche Limited, Canada | Herceptin Sc - 600 mg/vial | trastuzumab | 02480697 | early stage breast cancer | 15 Oct 2018 | Does Not Trigger Investigation |
2018 | Ipsen Biopharmaceuticals Canada Inc. | Cabometyx - 60 mg/tablet | cabozantinib (cabozantinib malate) | 02480840 | Cancer | 10 Oct 2018 | Within Guidelines |
2018 | Ipsen Biopharmaceuticals Canada Inc. | Cabometyx - 40 mg/tablet | cabozantinib (cabozantinib malate) | 02480832 | Cancer | 10 Oct 2018 | Within Guidelines |
2018 | Ipsen Biopharmaceuticals Canada Inc. | Cabometyx - 20 mg/tablet | cabozantinib (cabozantinib malate) | 02480824 | Cancer | 10 Oct 2018 | Within Guidelines |
2018 | Janssen Inc. | Erleada - 60 mg/tablet | apalutamide | 02478374 | non-metastatic castration-resistant prostate cancer | 27 Jul 2018 | Within Guidelines |
2018 | Janssen Inc. | Darzalex - 400 mg/vial | daratumumab | 02455978 | Cancer | 12 Jul 2016 | Within Guidelines |
2018 | Janssen Inc. | Darzalex - 100 mg/vial | daratumumab | 02455951 | Cancer | 12 Jul 2016 | Within Guidelines |
2018 | Janssen Inc. | SYMTUZA 800/150/200/10 - 1160 mg/tablet | darunavir/cobicistat/emtricitabine/tenofovir alafenamide | 2473720 | HIV | 26 Apr 2018 | VCU |
2018 | Knight Therapeutics Inc. | Probuphine - 80 mg/implant | buprenorphine hydrochloride | 02474921 | opioid dependence | 22 Nov 2018 | Within Guidelines |
2018 | Laboratoires Théa | MONOPROST - 50 mcg/mL | latanoprost | 2456230 | Intraocular pressure | 3 Jan 2018 | Within Guidelines |
2018 | Mallinckrodt Pharmaceuticals, LLC | OFIRMEV - 10 mg/mL | acetaminophen | 2408066 | Pain | 10 May 2018 | Subject to Investigation |
2018 | Medexus Inc. | Metoject Subcutaneous - 15 mg/syringe | methotrexate (methotrexate sodium) | 02454858 | Severe disabling psoriasis/psoriatic arthritis and Severe disabling rheumatoid arthritis | 30 Nov 2018 | Subject to Investigation |
2018 | Merck Canada Inc. | Pifeltro - 100 mg/tablet | doravirine | 02481545 | human immunodeficiency virus-1 | 14 Nov 2018 | Under Review |
2018 | Merck Canada Inc. | Steglujan 5/100 - 105 mg/tablet | ertugliflozin/sitagliptin (sitagliptin phosphate) | 02475901 | type 2 diabetes mellitus | 14 Jun 2018 | Within Guidelines |
2018 | Merck Canada Inc. | Steglujan 15/100 - 115 mg/tablet | ertugliflozin/sitagliptin (sitagliptin phosphate) | 02475928 | type 2 diabetes mellitus | 14 Jun 2018 | Within Guidelines |
2018 | Merck Canada Inc. | Segluromet 7.5/500 - 507.5 mg/tablet | ertugliflozine/chlorhydrate de metformine | 02476231 | type 2 diabetes mellitus | 06 Jul 2018 | Within Guidelines |
2018 | Merck Canada Inc. | Segluromet 7.5/1000 - 1007.5 mg/tablet | ertugliflozin/metformin hydrochloride | 02476258 | type 2 diabetes mellitus | 06 Jul 2018 | Within Guidelines |
2018 | Merck Canada Inc. | Segluromet 2.5/500 - 502.5 mg/tablet | ertugliflozin/metformin hydrochloride | 02476215 | type 2 diabetes mellitus | 06 Jul 2018 | Within Guidelines |
2018 | Merck Canada Inc. | Segluromet 2.5/1000 - 1002.5 mg/tablet | ertugliflozin/metformin hydrochloride | 02476223 | type 2 diabetes mellitus | 06 Jul 2018 | Within Guidelines |
2018 | Merck Canada Inc. | STEGLATRO - 5 mg/tablet | ertugliflozin | 2475510 | Diabetes | 28 May 2018 | Within Guidelines |
2018 | Merck Canada Inc. | STEGLATRO - 15 mg/tablet | ertugliflozin | 2475529 | Diabetes | 28 May 2018 | Within Guidelines |
2018 | Merck Canada Inc. | PREVYMIS - 20 mg/mL | letermovir | 2469367 | Antiviral | 20 Dec 2017 | Subject to Investigation |
2018 | Merck Canada Inc. | PREVYMIS - 240 mg/tablet | letermovir | 2469375 | Antiviral | 20 Dec 2017 | Subject to Investigation |
2018 | Merck Canada Inc. | PREVYMIS - 480 mg/tablet | letermovir | 2469383 | Antiviral | 20 Dec 2017 | Subject to Investigation |
2018 | Merck Canada Inc. | PREVYMIS - 20 mg/mL | letermovir | 2469405 | Antiviral | 20 Dec 2017 | Subject to Investigation |
2018 | Novartis Pharmaceuticals Canada Inc. | PAZEO - 7 mg/mL | olopatadine hydrochloride | 2458551 | Ocular itching | 12 Mar 2018 | Within Guidelines |
2018 | Novartis Pharmaceuticals Canada Inc. | Kisqali - 200 mg/tablet | ribociclib | 2473569 | Cancer | 26 Apr 2018 | Within Guidelines |
2018 | Novartis Pharmaceuticals Canada Inc. | Arzerra - 1000 mg/mL | ofatumumab | 02381567 | chronic lymphocytic leukemia | 14 May 2014 | Within Guidelines |
2018 | Novartis Pharmaceuticals Canada Inc. | Arzerra - 100 mg/mL | ofatumumab | 02381559 | chronic lymphocytic leukemia | 14 May 2014 | Within Guidelines |
2018 | Novo Nordisk Canada Inc. | Ozempic - 1 mg/dose | semaglutide | 2471469 | Diabetes | 23 Feb 2018 | Within Guidelines |
2018 | Novo Nordisk Canada Inc. | Ozempic - 1 N.A./dose | semaglutide | 2471477 | Diabetes | 23 Feb 2018 | Does Not Trigger Investigation |
2018 | Novo Nordisk Canada Inc. | Rebinyn - 500 N.A./IU | nonacog beta pegol | 2470187 | Hemophilia B | 4 Apr 2018 | Within Guidelines |
2018 | Novo Nordisk Canada Inc. | Rebinyn - 1000 N.A./IU | nonacog beta pegol | 2470268 | Hemophilia B | 4 Apr 2018 | Within Guidelines |
2018 | Novo Nordisk Canada Inc. | Rebinyn - 2000 N.A./IU | nonacog beta pegol | 2470276 | Hemophilia B | 4 Apr 2018 | Within Guidelines |
2018 | Novo Nordisk Canada Inc. | Zonovate - 250 N.A./IU | turoctocog alfa | 2435187 | Hemophilia A | 2 Apr 2018 | Within Guidelines |
2018 | Novo Nordisk Canada Inc. | Zonovate - 500 N.A./IU | turoctocog alfa | 2435195 | Hemophilia A | 2 Apr 2018 | Within Guidelines |
2018 | Novo Nordisk Canada Inc. | Zonovate - 1000 N.A./IU | turoctocog alfa | 2435209 | Hemophilia A | 3 Apr 2018 | Within Guidelines |
2018 | Novo Nordisk Canada Inc. | Zonovate - 2000 N.A./IU | turoctocog alfa | 2435225 | Hemophilia A | 3 Apr 2018 | Within Guidelines |
2018 | Novo Nordisk Canada Inc. | Zonovate - 3000 N.A./IU | turoctocog alfa | 2435233 | Hemophilia A | 3 Apr 2018 | Within Guidelines |
2018 | Octapharma Canada Inc. | Nuwiq - 4000 IU/vial | simoctocog alfa | 02474069 | hemophilia A (congenital factor VIII deficiency) | 25 Jul 2018 | Within Guidelines |
2018 | Octapharma Canada Inc. | Nuwiq - 3000 IU/vial | simoctocog alfa | 02474050 | hemophilia A (congenital factor VIII deficiency) | 25 Jul 2018 | Within Guidelines |
2018 | Pfizer Canada Inc. | Eucrisa - 20 mg/gram | crisaborole | 02476991 | mild to moderate atopic dermatitis | 30 Oct 2018 | Within Guidelines |
2018 | Pfizer Canada Inc. | TRUMENBA - 60/60 - 120 mcg/syringe | neisseria meningitidis group B recombinant lipoprotein 2086 subfamily A/B | 2468751 | Invasive meningococcal disease | 31 Jan 2018 | Within Guidelines |
2018 | Pfizer Canada Inc. | XELJANZ XR -- 11 mg/tablet | tofacitinib citrate | 2470608 | Rheumatoid arthritis | 29 Mar 2018 | Does Not Trigger Investigation |
2018 | Pfizer Canada Inc. | BESPONSA - 0.9 mg/vial | inotuzumab ozogamicin | 2473909 | Cancer | 3 May 2018 | Within Guidelines |
2018 | Purdue Pharma | BELBUCA - 75 mcg/film | buprenorphine hydrochloride | 2465221 | Pain | 17 Jan 2018 | Within Guidelines |
2018 | Purdue Pharma | BELBUCA - 150 mcg/film | buprenorphine hydrochloride | 2465248 | Pain | 17 Jan 2018 | Within Guidelines |
2018 | Purdue Pharma | BELBUCA - 300 mcg/film | buprenorphine hydrochloride | 2465256 | Pain | 17 Jan 2018 | Within Guidelines |
2018 | Purdue Pharma | BELBUCA - 450 mcg/film | buprenorphine hydrochloride | 2465264 | Pain | 17 Jan 2018 | Within Guidelines |
2018 | Purdue Pharma | Foquest - 25 mg/capsule | methylphenidate hydrochloride | 2470292 | ADHD | 14 Dec 2017 | Within Guidelines |
2018 | Purdue Pharma | Foquest - 35 mg/capsule | methylphenidate hydrochloride | 2470306 | ADHD | 14 Dec 2017 | Within Guidelines |
2018 | Purdue Pharma | Foquest - 45 mg/capsule | methylphenidate hydrochloride | 2470314 | ADHD | 14 Dec 2017 | Within Guidelines |
2018 | Purdue Pharma | Foquest - 55 mg/capsule | methylphenidate hydrochloride | 2470322 | ADHD | 14 Dec 2017 | Within Guidelines |
2018 | Purdue Pharma | Foquest - 70 mg/capsule | methylphenidate hydrochloride | 2470330 | ADHD | 14 Dec 2017 | Within Guidelines |
2018 | Purdue Pharma | Foquest - 85 mg/capsule | methylphenidate hydrochloride | 2470349 | ADHD | 14 Dec 2017 | Within Guidelines |
2018 | Purdue Pharma | Foquest - 100 mg/capsule | methylphenidate hydrochloride | 2470357 | ADHD | 11 Jan 2018 | Within Guidelines |
2018 | Sanofi-Aventis Canada Inc. | Dupixent - 150 mg/mL | dupilumab | 2470365 | Atopic dermatitis | 7 Feb 2018 | VCU |
2018 | Sanofi-aventis Canada Inc. | Soliqua - 3 /pen | insulin glargine/lixisenatide | 02478293 | type 2 diabetes mellitus | 12 Sep 2018 | Does Not Trigger Investigation |
2018 | Sanofi-Aventis Canada Inc. | Praluent - 75 mg/mL (syringe) | alirocumab | 2453754 | Cholesterol | 13 Aug 2016 (Patented 9 Jan 2018) | VCU |
2018 | Sanofi-Aventis Canada Inc. | Praluent - 150 mg/mL (syringe) | alirocumab | 2453762 | Cholesterol | 13 Aug 2016 (Patented 9 Jan 2018) | VCU |
2018 | Sanofi-Aventis Canada Inc. | Praluent - 75 mg/mL (pen) | alirocumab | 2453819 | Cholesterol | 18 May 2016 (Patented 9 Jan 2018) | VCU |
2018 | Sanofi-Aventis Canada Inc. | Praluent - 150 mg/mL (pen) | alirocumab | 2453835 | Cholesterol | 29 Apr 2016 (Patented 9 Jan 2018) | VCU |
2018 | Sanofi-aventis Canada Inc. | Kevzara - 200 mg/pen | sarilumab | 02472988 | moderately to severely active rheumatoid arthritis | 21 Jun 2018 | Within Guidelines |
2018 | Sanofi-aventis Canada Inc. | Kevzara - 150 mg/pen | sarilumab | 02472961 | moderately to severely active rheumatoid arthritis | 21 Jun 2018 | Within Guidelines |
2018 | Servier Canada Inc. | Folotyn - 20 mg/mL | pralatrexate | 02481820 | relapsed or refractory peripheral T-cell lymphoma | 04 Sep 2018 | Within Guidelines |
2018 | Servier Canada Inc. | Beleodaq - 500 mg/vial | belinostat | | Lynphoma | 28 Nov 2018 | Within Guidelines |
2018 | Shire Pharma Canada Inc. | Takhzyro - 150 mg/mL | lanadelumab | 02480948 | prevention of attacks of hereditary angioedema | 31 Oct 2018 | Subject to Investigation |
2018 | Sprout Pharmaceuticals | Addyi - 100 mg/tablet | flibanserin | 02473550 | hypoactive sexual desire disorder | 13 Nov 2018 | Within Guidelines |
2018 | Sunovion Pharmaceuticals Canada Inc. | Cubicin RF - 500 mg/vial | daptomycin | 2465493 | Infections | 17 Jan 2018 | Does Not Trigger Investigation |
2018 | Takeda Canada Inc. | Alunbrig 90/180 - 1 N.A./pack | brigatinib | 02479230 | Cancer | 31 Aug 2018 | Within Guidelines |
2018 | Takeda Canada Inc. | Alunbrig - 180 mg/tablet | brigatinib | 02479222 | Cancer | 31 Aug 2018 | Within Guidelines |
2018 | Takeda Canada Inc. | Alunbrig - 90 mg/tablet | brigatinib | 02479214 | Cancer | 31 Aug 2018 | Within Guidelines |
2018 | Takeda Canada Inc. | Alunbrig - 30 mg/tablet | brigatinib | 02479206 | Cancer | 31 Aug 2018 | Within Guidelines |
2018 | Valeant Canada Lp | CONTRAVE 8/90 - 98 mg/tablet | naltrexone hydrochloride/bupropion hydrochloride | 2472945 | Chronic weight management | 16 Mar 2018 | Within Guidelines |
2018 | Vertex Pharmaceuticals Canada Inc. | Symdeko 100/150/150 - 1 N.A./pack | ivacaftor/ivacaftor/tezacaftor | 02478080 | cystic fibrosis | 28 Jun 2018 | Within Guidelines |
2018 | ViiV HealthCare ULC | Juluca 50/25 - 75 mg/tablet | dolutegravir (dolutegravir sodium)/rilpivirine (rilpivirine hydrochloride) | 02475774 | human immunodeficiency virus-1 | 04 Jun 2018 | Within Guidelines |